Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-302
- Development stage
- Preclinical
- Lead developer
- Coya Therapeutics
01
Overview
AD-302 is a preclinical-stage drug candidate being developed by Addpharma, a South Korean pharmaceutical company and subsidiary of Yuhan Corporation, for the treatment of pain. It is classified as a "New Drug" (신약) within the company's pipeline, distinguishing it from their "Improved New Drug" (개량신약) projects which typically focus on new formulations or combinations of existing agents. As of early 2024, specific details regarding its molecular target, mechanism of action, and chemical modality (such as whether it is a small molecule or biologic) have not been publicly disclosed by the developer. The project is currently undergoing preclinical research to evaluate its safety and efficacy for nervous system indications.
Beyond the preview
Go deeper on AD-302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-302.